April 2, 2026: Dr. Markowitz is approved as Project Leader for a Cancer Center Support Grant Research Supplement (originally conceptualized by Dr. Jing, with Dr. Libutti as PI) to generate immuno-organoids as a scalable, autologous tumor-immune model for evaluating immunotherapies
March 24, 2026: Dr. Markowitz presents at the CMI/CPC Mini Retreat on "Diet, Metabolism, and Cancer"
Geoffrey J. Markowitz, PhD, is an RBHS Instructor in the Department of Medicine at the Rutgers Robert Wood Johnson Medical School and within the Division of Medical Oncology, Section of Cancer Immunotherapy at the Rutgers Cancer Institute. Dr.
Immunotherapy has revolutionized the cancer treatment landscape. T cells are critical determinants of the anti-tumor immune response, and while their therapeutic modulation has been game-changing, a substantial portion of patients do not respond to treatment.
